Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study

Onsun N., Akaslan T. Ç., Sallahoglu K., Gülcan A. S., Bulut H., Yabacı A.

JOURNAL OF DERMATOLOGICAL TREATMENT, vol.33, no.3, pp.1727-1732, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.1080/09546634.2021.1901845
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1727-1732
  • Keywords: Psoriasis, adipokines, weight parameters, leptin, adiponectin, omentin, LEPTIN PRODUCTION, SERUM LEPTIN, EXPRESSION
  • Bezmialem Vakıf University Affiliated: Yes


Background: Psoriasis is a chronic inflammatory disease associated with obesity and metabolic syndrome. Adipokines are thought to be a link between psoriasis and obesity. Leptin, adiponectin, and omentin are bioactive adipokines thought to play a role in both metabolic comorbidities and inflammation. Anti-tumour necrosis factor alfa (anti-TNF-alpha) agents are effective for psoriasis treatment, although significant weight gain has been reported during anti-TNF-alpha therapy. The interleukin 12/23 (IL 12/23) inhibitor ustekinumab is also effective for psoriasis treatment. We compared the effects of three anti-TNF-alpha drugs and an IL-12/23 inhibitor on adipokines and weight gain during treatment.